Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on January 25, 2006
Japanese Journal of Clinical Oncology 2006 36(1):55-59; doi:10.1093/jjco/hyi214
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/1/55    most recent
hyi214v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kim, Y.-A
Right arrow Articles by Jeung, H.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, Y.-A
Right arrow Articles by Jeung, H.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

Case Report

Intermediate Dose 5-Fluorouracil-Induced Encephalopathy

Yeon-A Kim1, Hyun Cheol Chung1,2, Hye Jin Choi1, Sun Young Rha2, Jin Sil Seong3 and Hei-Cheul Jeung2

1 Department of Internal Medicine, 2 Cancer Metastasis Research Center, Yonsei Cancer Center and 3 Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

For reprints and all correspondence: Hei-Cheul Jeung, Cancer Metastasis Research Center, Yosnei Cancer Center, Yonsei University College of Medicine, 134 Shinchon-Dong, Seodaemoon-Ku, CPO box #8044, Seoul 120-752, Korea. E-mail: jeunghc1123{at}yumc.yonsei.ac.kr

Received August 1, 2005; accepted November 11, 2005

As an acute neurotoxicity, high dose 5-fluorouracil (5-FU)-induced encephalopathy is well-known, but encephalopathy associated with lower dose is rarely reported. Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m2, continuous infusion for 5 days q4 weeks. At the second and the fourth cycles of chemotherapy, sudden confusion, cognitive dysfunction and disorientation occurred during 5-FU infusion. They were accompanied by hyperammonemia in the absence of focal neurological deficits or structural abnormalities. These symptoms completely disappeared and the serum ammonia level returned to normal after discontinuation of 5-FU and conservative care. In order to investigate a possible deficit of dihydropyrimidine dehydrogenase (DPD), we checked its mRNA level before and after treatment using real-time PCR. The patient's pre-treatment level was 80% compared with reference group, and it was elevated up to 187% of initial after 5-FU treatment, implying that that his encephalopathy may be 5-FU catabolite type rather than DPD deficiency. In conclusion, we report that encephalopathy can develop even with the dose of 5-FU lower than ever reported, and it should be considered as a differential diagnosis for proper management.

Key Words: 5-fluorouracil • encephalopathy • anal cancer • hyperammonemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.